Kymera Therapeutics, Inc.
US ˙ NasdaqGM ˙ US5015751044

SecurityKYMR / Kymera Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership140,507 shares
Latest Disclosed Value $ 10,932,850
Barclays Plc ownership in KYMR / Kymera Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 140,507 shares of Kymera Therapeutics, Inc. (US:KYMR) valued at $10,932,850 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 155,144 shares of Kymera Therapeutics, Inc.. This represents a change in shares of -9.43% during the quarter. The current value of the position is $10,483,227 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (KYMR) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

KYMR / Kymera Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F KYMERA THERAPEUTICS COM 501575104 140,507 -14,637 -9.43 10,933 24.50 0.0026
2026-03-31 2025-09-30 13F/A-3 KYMERA THERAPEUTICS COM 501575104 155,144 11,963 8.36 8,781 40.54 0.0019
2026-03-19 2025-09-30 13F/A-2 KYMERA THERAPEUTICS COM 501575104 91,755 -51,426 4,343 0.0012
2025-11-12 2025-09-30 13F KYMERA THERAPEUTICS COM 501575104 155,144 11,963 8,781 0.0019
2026-02-27 2025-06-30 13F/A-2 KYMERA THERAPEUTICS COM 501575104 143,181 57,969 68.03 6,248 167.92 0.0014
2025-08-14 2025-06-30 13F/A-1 KYMERA THERAPEUTICS COM 501575104 143,181 57,969 6 0.0014
2025-08-13 2025-06-30 13F KYMERA THERAPEUTICS COM 501575104 143,181 57,969 6 0.0005
2026-03-17 2025-03-31 13F/A-1 KYMERA THERAPEUTICS COM 501575104 85,212 -15,793 -15.64 2,332 -42.60 0.0007
2025-05-15 2025-03-31 13F KYMERA THERAPEUTICS COM 501575104 85,212 -15,793 2 0.0007
2026-03-19 2024-12-31 13F/A-1 KYMERA THERAPEUTICS COM 501575104 101,005 9,250 10.08 4,063 -6.43 0.0011
2025-02-13 2024-12-31 13F KYMERA THERAPEUTICS COM 501575104 101,005 9,250 4 0.0011
2026-03-31 2024-09-30 13F/A-2 KYMERA THERAPEUTICS COM 501575104 91,755 42,662 86.90 4,343 196.38 0.0012
2024-11-19 2024-09-30 13F/A-1 KYMERA THERAPEUTICS COM 501575104 91,755 42,662 4 0.0012
2024-11-15 2024-09-30 13F KYMERA THERAPEUTICS COM 501575104 91,755 42,662 4 0.0004
2026-03-23 2024-06-30 13F/A-1 KYMERA THERAPEUTICS COM 501575104 49,093 -270,808 -84.65 1,465 -88.61 0.0004
2024-08-14 2024-06-30 13F KYMERA THERAPEUTICS COM 501575104 49,093 -270,808 1 0.0004
2026-03-24 2024-03-31 13F/A-1 KYMERA THERAPEUTICS COM 501575104 319,901 -61,880 -16.21 12,860 32.30 0.0045
2024-05-15 2024-03-31 13F KYMERA THERAPEUTICS COM 501575104 319,901 -61,880 13 0.0045
2026-03-25 2023-12-31 13F/A-1 KYMERA THERAPEUTICS COM 501575104 381,781 -7,695 -1.98 9,720 79.57 0.0036
2024-02-15 2023-12-31 13F KYMERA THERAPEUTICS COM 501575104 381,781 -7,695 10 0.0036
2026-03-26 2023-09-30 13F/A-1 KYMERA THERAPEUTICS COM 501575104 389,476 4,493 1.17 5,414 -38.84 0.0034
2023-11-07 2023-09-30 13F KYMERA THERAPEUTICS COM 501575104 389,476 4,493 5 0.0034
2026-03-30 2023-06-30 13F/A-2 KYMERA THERAPEUTICS COM 501575104 384,983 25,055 6.96 8,851 -17.01 0.0056
2023-09-20 2023-06-30 13F/A-1 KYMERA THERAPEUTICS COM 501575104 384,983 25,055 9 0.0056
2023-08-03 2023-06-30 13F KYMERA THERAPEUTICS COM 501575104 384,983 25,055 9 0.0056
2026-03-30 2023-03-31 13F/A-1 KYMERA THERAPEUTICS COM 501575104 359,928 -30,722 -7.86 10,665 9.37 0.0049
2023-05-04 2023-03-31 13F KYMERA THERAPEUTICS COM 501575104 359,928 -30,722 11 0.0049
2026-03-30 2022-12-31 13F/A-1 KYMERA THERAPEUTICS COM 501575104 390,650 37,656 10.67 9,751 26.87 0.0044
2023-02-13 2022-12-31 13F KYMERA THERAPEUTICS COM 501575104 390,650 37,656 10 0.0044
2022-11-03 2022-09-30 13F KYMERA THERAPEUTICS COM 501575104 352,994 119,857 51.41 7,685 67.43 0.0084
2022-08-12 2022-06-30 13F KYMERA THERAPEUTICS COM 501575104 233,137 226,360 3,340.12 4,590 1,499.30 0.0028
2022-05-16 2022-03-31 13F KYMERA THERAPEUTICS COM 501575104 6,777 6,777 287 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F KYMERA THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-03-19 2025-09-30 13F/A KYMERA THERAPEUTICS OPT Call 5,500 260 n/a n/a n/a
2026-03-17 2025-03-31 13F/A KYMERA THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F KYMERA THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2026-03-19 2024-12-31 13F/A KYMERA THERAPEUTICS OPT Call 5,500 0.00 221 -15.00 n/a n/a n/a
2025-02-13 2024-12-31 13F KYMERA THERAPEUTICS OPT Call 5,500 0 n/a n/a n/a
2024-11-19 2024-09-30 13F/A KYMERA THERAPEUTICS OPT Call 5,500 0 n/a n/a n/a
2026-03-31 2024-09-30 13F/A KYMERA THERAPEUTICS OPT Call 5,500 260 n/a n/a n/a
2024-11-15 2024-09-30 13F KYMERA THERAPEUTICS OPT Call 5,500 0 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F KYMERA THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-03-19 2025-09-30 13F/A KYMERA THERAPEUTICS OPT Put 31,400 1,486 n/a n/a n/a
2026-03-19 2024-12-31 13F/A KYMERA THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-13 2024-12-31 13F KYMERA THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2024-11-19 2024-09-30 13F/A KYMERA THERAPEUTICS OPT Put 31,400 1 n/a n/a n/a
2026-03-31 2024-09-30 13F/A KYMERA THERAPEUTICS OPT Put 31,400 1,486 n/a n/a n/a
2024-11-15 2024-09-30 13F KYMERA THERAPEUTICS OPT Put 31,400 1 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.